Solta Medical, Inc. (SLTM) said it has received a new FDA 510(k) clearance of its Fraxel DUAL 1550/1927 laser system for the treatment of pigmented lesions such as, but not limited to lentigos or (age spots), solar lentigos or sun spots and ephelides or freckles.
In addition to the treatment of pigmented lesions, the Fraxel DUAL system is indicated for use in dermatological procedures requiring the coagulation of soft tissue, as well as for skin resurfacing procedures. Specific additional indications include actinic keratosis, melasma, treatment of periorbital wrinkles, acne scars and surgical scars.
The Fraxel DUAL system is an unsurpassed breakthrough skin resurfacing technology that renews skin and helps maintain skin's youthful glow despite a person's age or skin color, with minimal discomfort and downtime.
For comments and feedback: editorial@rttnews.com